CDK12 pathogenic variants
About
Gene context: CDK12
Biomarker Type: Germline Variant
Present: True
Chromosome: 17
Requires Pathogenic: True
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | CDK12 pathogenic variants | Prostate Adenocarcinoma | Olaparib | |
| FDA (1) | CDK12 pathogenic variants | Prostate Adenocarcinoma | Enzalutamide, Talazoparib |